{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:28:25Z","timestamp":1786883305739,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203126"],"award-info":[{"award-number":["82203126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272890"],"award-info":[{"award-number":["82272890"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023TQ0390"],"award-info":[{"award-number":["2023TQ0390"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["YTP-SYSUCC-0071"],"award-info":[{"award-number":["YTP-SYSUCC-0071"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["YTP-SYSUCC-0077"],"award-info":[{"award-number":["YTP-SYSUCC-0077"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFA0915703"],"award-info":[{"award-number":["2023YFA0915703"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jncc.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:39:40Z","timestamp":1779190780000},"page":"410-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses"],"prefix":"10.1016","volume":"6","author":[{"given":"Zhicheng","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minke","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jncc.2026.04.002_bib0001","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2468-1253(19)30178-5","article-title":"Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west","volume":"4","author":"Lu","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.002_bib0002","doi-asserted-by":"crossref","first-page":"554","DOI":"10.21147\/j.issn.1000-9604.2022.06.02","article-title":"Burden of liver cancer: from epidemiology to prevention","volume":"34","author":"Li","year":"2022","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.002_bib0003","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.002_bib0004","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.002_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.jncc.2026.04.002_bib0006","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.addr.2012.09.011","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"64","author":"Jain","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.002_bib0007","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO","volume":"31","author":"Chen","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jncc.2026.04.002_bib0008","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ejso.2019.03.042","article-title":"Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study","volume":"45","author":"Xiang","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.002_bib0009","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1148\/radiol.12111550","article-title":"Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib","volume":"263","author":"Pinter","year":"2012","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.002_bib0010","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00330-016-4511-3","article-title":"Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus","volume":"27","author":"Choi","year":"2017","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.jncc.2026.04.002_bib0011","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/liv.13719","article-title":"Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein","volume":"38","author":"Kim","year":"2018","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.jncc.2026.04.002_bib0012","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1586\/14737140.8.11.1743","article-title":"Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease","volume":"8","author":"Strebel","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.002_bib0013","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jncc.2026.04.002_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.phrs.2018.06.021","article-title":"Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis","volume":"135","author":"Feng","year":"2018","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.002_bib0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1148\/radiol.13130150","article-title":"Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses","volume":"269","author":"Choi","year":"2013","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.002_bib0016","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1148\/radiol.14131946","article-title":"Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib\u2013a retrospective controlled study","volume":"272","author":"Zhu","year":"2014","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.002_bib0017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000530495","article-title":"Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"issue":"4","key":"10.1016\/j.jncc.2026.04.002_bib0018","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3350\/cmh.2022.0294","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"28","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"10.1016\/j.jncc.2026.04.002_bib0019","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines)","volume":"53","author":"Hasegawa","year":"2023","journal-title":"Hepatol Res"},{"issue":"6","key":"10.1016\/j.jncc.2026.04.002_bib0020","first-page":"498","article-title":"Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians","volume":"75","author":"Moris","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.002_bib0021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/djs464","article-title":"Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial","volume":"105","author":"Shi","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.002_bib0022","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12916-022-02608-6","article-title":"One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma","volume":"20","author":"Lai","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.jncc.2026.04.002_bib0023","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","article-title":"Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial","volume":"174","author":"Lai","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.jncc.2026.04.002_bib0024","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jncc.2026.04.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211063848","article-title":"Toripalimab combined with hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma","volume":"20","author":"Xu","year":"2021","journal-title":"Technol Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.jncc.2026.04.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2021.06.008","article-title":"Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis","volume":"32","author":"Li","year":"2021","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.002_bib0027","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.002_bib0028","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jncc.2026.04.002_bib0029","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12885-018-4144-9","article-title":"Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study","volume":"18","author":"Ye","year":"2018","journal-title":"BMC Cancer"},{"issue":"3_suppl","key":"10.1016\/j.jncc.2026.04.002_bib0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jncc.2026.04.002_bib0031","doi-asserted-by":"crossref","first-page":"29416","DOI":"10.18632\/oncotarget.15075","article-title":"Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.jncc.2026.04.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2018.03.027","article-title":"Comparison of stable and unstable ethiodized oil emulsions for transarterial chemoembolization of hepatocellular carcinoma: results of a single-center double-blind prospective randomized controlled trial","volume":"29","author":"He","year":"2018","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.002_bib0033","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"10.1016\/j.jncc.2026.04.002_bib0034","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1158\/0008-5472.CAN-12-1340","article-title":"Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7)","volume":"72","author":"Malofeeva","year":"2012","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jncc.2026.04.002_bib0035","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.bcp.2009.07.006","article-title":"Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy","volume":"78","author":"Theile","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.jncc.2026.04.002_bib0036","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/jpm11101041","article-title":"TRANS-TACE: prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma","volume":"11","author":"Granito","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.jncc.2026.04.002_bib0037","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14737140.2023.2181162","article-title":"TKIs in combination with immunotherapy for hepatocellular carcinoma","volume":"23","author":"Stefanini","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"10.1016\/j.jncc.2026.04.002_bib0038","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.7150\/thno.56490","article-title":"ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM","volume":"11","author":"Zhou","year":"2021","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.jncc.2026.04.002_bib0039","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/neuonc\/noac135","article-title":"Non-metabolic functions of phosphofructokinase-1 orchestrate tumor cellular invasion and genome maintenance under bevacizumab therapy","volume":"25","author":"Lim","year":"2023","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2026.04.002_bib0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542600058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542600058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:48:10Z","timestamp":1786880890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266700542600058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S266700542600058X"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2026.04.002","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}